Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy

Area of Science:

• Immunology
• Virology
• Pharmacology

Background:

• HIV infection causes progressive immune deficiency.
• Evaluating immune recovery in HIV patients is crucial for treatment efficacy.
• Darunavir/ritonavir (DRV/r) is an established antiretroviral regimen.

Purpose of the Study:

• To assess the recovery of functional immunity in HIV-1 infected patients receiving a DRV/r-based regimen.
• To evaluate changes in CD4+ cell counts and immune cell proliferation.
• To determine the association between virologic suppression and immune reconstitution.

Main Methods:

• Prospective substudy of patients from the GRACE (Gender, Race, And Clinical Experience) study.
• Treatment-experienced, HIV-1 infected patients received a DRV/r-based regimen.
• Assessed viral load, CD4+ cell counts, CD8+ percentages, and lymphocyte proliferation responses.

Main Results:

• 59% of patients achieved viral suppression (<50 copies/mL).
• Median CD4+ cell count increased from 222 to 398 cells/mm(3) at 48 weeks.
• Significant increases in CD4+ T-cell proliferation and cytokine production were observed.

Conclusions:

• DRV/r-based therapy promotes CD4+ cell recovery in HIV-1 infected patients.
• The regimen is associated with progressive restoration of functional immunity over 48 weeks.
• This highlights the importance of effective antiretroviral therapy for immune reconstitution.